Quarterly Publication of Fosun Pharmaceutical in 2010
Fosun Pharmaceutical has released its 2010 Quarterly Publication on April 29th, which has shown that Fosun Pharmaceutical has realized operating revenue of RMB 1.073 billion 27.34% higher than that of the same period last year; net profits belonging to parent company of RMB 300 million, 91.30% higher than that of the same period of previous year and net profit per share of RMB 0.27, 92.86% higher than that of the same period last year. It is understood that substantial increase for company performance is due to the following aspects: rapid growth for the performance of core pharmaceutical enterprises and return on equity transfer.
Reinforcement of Marketing Construction and Rapid Growth of Main Businesses:
In the first quarter of 2010, the company is embarked on product management and marketing team building so as to speed up creating integration platform and realize rapid development of pharmaceutical businesses. It is understood that its core pharmaceutical enterprises of Chongqing Yaoyou and Shine Star (Hubei) Biological Engineering Co., Ltd. have realized rapid growth of sales income in the first quarter of 2010, with 40% increase in the revenue. Through strengthening the marketing, the construction for professional management team in the fields of diabetes mellitus, hepatopathy and malaria therapy has been further strengthened, and main products are continuing to maintain leading position in segmented markets.
On the aspect of the drugs retail, the subordinate companies of For Me Pharmacy and Jinxiang Pharmacy continue to lead in pharmaceutical retail business of their own regions, the number of the pharmacies and profitability take the lead in regional markets.
Improvement of R&D System and Continuous Increase to Contribution;
In the first quarter of 2010, the company continues to improve R&D system on drug of “Combination of Imitation and Innovation” and further advances R&D on generic drugs and innovative drugs through R&D platform under Chongqing Pharmaceutical Research Institute and Fosun Omni, Chongqing Fosun Pharmaceutical Research Co., Ltd., and Fuhong Hanlin so as to strengthen its innovation capability and product competitiveness and positively follow the latest technical front in global pharmaceutical industry.
Furthermore, the company has finished the disposal for 9.56 % equity transfer of Forte, RMB 195 million as the transfer earnings after tax has been entered into the performance of the first quarter of 2010.
In the future, the company will continue to promote human health for the mission and follow the brand idea of “Innovation for Good Health” to positively advance the strategy of “Endogenous Growth, Extensive Expansion and Integrated Development” around core pharmaceutical businesses to make it maintain healthy development.
Reinforcement of Marketing Construction and Rapid Growth of Main Businesses:
In the first quarter of 2010, the company is embarked on product management and marketing team building so as to speed up creating integration platform and realize rapid development of pharmaceutical businesses. It is understood that its core pharmaceutical enterprises of Chongqing Yaoyou and Shine Star (Hubei) Biological Engineering Co., Ltd. have realized rapid growth of sales income in the first quarter of 2010, with 40% increase in the revenue. Through strengthening the marketing, the construction for professional management team in the fields of diabetes mellitus, hepatopathy and malaria therapy has been further strengthened, and main products are continuing to maintain leading position in segmented markets.
On the aspect of the drugs retail, the subordinate companies of For Me Pharmacy and Jinxiang Pharmacy continue to lead in pharmaceutical retail business of their own regions, the number of the pharmacies and profitability take the lead in regional markets.
Improvement of R&D System and Continuous Increase to Contribution;
In the first quarter of 2010, the company continues to improve R&D system on drug of “Combination of Imitation and Innovation” and further advances R&D on generic drugs and innovative drugs through R&D platform under Chongqing Pharmaceutical Research Institute and Fosun Omni, Chongqing Fosun Pharmaceutical Research Co., Ltd., and Fuhong Hanlin so as to strengthen its innovation capability and product competitiveness and positively follow the latest technical front in global pharmaceutical industry.
Furthermore, the company has finished the disposal for 9.56 % equity transfer of Forte, RMB 195 million as the transfer earnings after tax has been entered into the performance of the first quarter of 2010.
In the future, the company will continue to promote human health for the mission and follow the brand idea of “Innovation for Good Health” to positively advance the strategy of “Endogenous Growth, Extensive Expansion and Integrated Development” around core pharmaceutical businesses to make it maintain healthy development.